Ameriprise’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $79.4M | Buy |
239,941
+58,804
| +32% | +$20M | 0.02% | 648 |
|
|
2025
Q4 | $72M | Sell |
181,137
-44,742
| -20% | -$19.8M | 0.02% | 692 |
|
|
2025
Q3 | $103M | Buy |
225,879
+32,230
| +17% | +$13.1M | 0.02% | 556 |
|
|
2025
Q2 | $63.1M | Buy |
193,649
+84,513
| +77% | +$23.4M | 0.02% | 748 |
|
|
2025
Q1 | $29.5M | Sell |
109,136
-18,937
| -15% | -$4.87M | 0.01% | 1098 |
|
|
2024
Q4 | $30.1M | Sell |
128,073
-9,765
| -7% | -$2.57M | 0.01% | 1110 |
|
|
2024
Q3 | $37.9M | Sell |
137,838
-100,482
| -42% | -$26.2M | 0.01% | 979 |
|
|
2024
Q2 | $57.9M | Buy |
238,320
+43,595
| +22% | +$6.88M | 0.02% | 732 |
|
|
2024
Q1 | $29.1M | Sell |
194,725
-182,934
| -48% | -$30.5M | 0.01% | 1072 |
|
|
2023
Q4 | $72.3M | Sell |
377,659
-328,541
| -47% | -$56M | 0.02% | 628 |
|
|
2023
Q3 | $125M | Buy |
706,200
+80,862
| +13% | +$15.4M | 0.04% | 413 |
|
|
2023
Q2 | $119M | Buy |
625,338
+422,168
| +208% | +$83.7M | 0.04% | 454 |
|
|
2023
Q1 | $40.7M | Buy |
203,170
+155,795
| +329% | +$32.7M | 0.01% | 852 |
|
|
2022
Q4 | $11.3M | Buy |
47,375
+37,804
| +395% | +$8.06M | ﹤0.01% | 1641 |
|
|
2022
Q3 | $1.91M | Sell |
9,571
-914
| -9% | -$174K | ﹤0.01% | 2803 |
|
|
2022
Q2 | $1.53M | Sell |
10,485
-2,167
| -17% | -$307K | ﹤0.01% | 2926 |
|
|
2022
Q1 | $2.02M | Buy |
12,652
+115
| +0.9% | +$17.5K | ﹤0.01% | 2907 |
|
|
2021
Q4 | $2.07M | Buy |
12,537
+1,823
| +17% | +$339K | ﹤0.01% | 2940 |
|
|
2021
Q3 | $2.02M | Sell |
10,714
-45,941
| -81% | -$8.62M | ﹤0.01% | 2871 |
|
|
2021
Q2 | $9.61M | Buy |
56,655
+7,274
| +15% | +$1.07M | ﹤0.01% | 1972 |
|
|
2021
Q1 | $7.03M | Buy |
49,381
+7,636
| +18% | +$1.15M | ﹤0.01% | 2158 |
|
|
2020
Q4 | $5.42M | Buy |
41,745
+14,176
| +51% | +$1.89M | ﹤0.01% | 2213 |
|
|
2020
Q3 | $4.02M | Buy |
27,569
+2,514
| +10% | +$357K | ﹤0.01% | 2241 |
|
|
2020
Q2 | $3.71M | Buy |
25,055
+11,308
| +82% | +$1.52M | ﹤0.01% | 2272 |
|
|
2020
Q1 | $1.5M | Buy |
13,747
+781
| +6% | +$90.2K | ﹤0.01% | 2628 |
|
|
2019
Q4 | $1.49M | Buy |
12,966
+46
| +0.4% | +$4.59K | ﹤0.01% | 2879 |
|
|
2019
Q3 | $1.04M | Buy |
12,920
+789
| +7% | +$62.4K | ﹤0.01% | 3006 |
|
|
2019
Q2 | $880K | Sell |
12,131
-18,006
| -60% | -$1.38M | ﹤0.01% | 3116 |
|
|
2019
Q1 | $2.82M | Buy |
30,137
+274
| +0.9% | +$22.9K | ﹤0.01% | 2569 |
|
|
2018
Q4 | $2.17M | Sell |
29,863
-27,186
| -48% | -$2.09M | ﹤0.01% | 2614 |
|
|
2018
Q3 | $4.99M | Sell |
57,049
-47,219
| -45% | -$4.75M | ﹤0.01% | 2339 |
|
|
2018
Q2 | $10.3M | Buy |
104,268
+79,311
| +318% | +$7.87M | ﹤0.01% | 1716 |
|
|
2018
Q1 | $2.97M | Buy |
24,957
+22,357
| +860% | +$2.88M | ﹤0.01% | 2513 |
|
|
2017
Q4 | $331K | Buy |
2,600
+428
| +20% | +$53.8K | ﹤0.01% | 3331 |
|
|
2017
Q3 | $255K | Buy |
+2,172
| New | +$185K | ﹤0.01% | 3440 |
|
|
2016
Q4 | – | Sell |
-21,571
| Closed | -$1.46M | – | 3875 |
|
|
2016
Q3 | $1.46M | Buy |
+21,571
| New | +$1.52M | ﹤0.01% | 2732 |
|
|
2016
Q1 | – | Sell |
-16,345
| Closed | -$1.54M | – | 3752 |
|
|
2015
Q4 | $1.54M | Sell |
16,345
-1,790
| -10% | -$166K | ﹤0.01% | 2740 |
|
|
2015
Q3 | $1.46M | Buy |
18,135
+13,107
| +261% | +$1.46M | ﹤0.01% | 2792 |
|
|
2015
Q2 | $603K | Buy |
5,028
+2,054
| +69% | +$245K | ﹤0.01% | 3359 |
|
|
2015
Q1 | $310K | Sell |
2,974
-6,820
| -70% | -$691K | ﹤0.01% | 3405 |
|
|
2014
Q4 | $951K | Sell |
9,794
-428,783
| -98% | -$39.7M | ﹤0.01% | 2897 |
|
|
2014
Q3 | $34.3M | Buy |
438,577
+354,342
| +421% | +$22.9M | 0.02% | 664 |
|
|
2014
Q2 | $5.32M | Sell |
84,235
-135,276
| -62% | -$8.04M | ﹤0.01% | 2040 |
|
|
2014
Q1 | $14.7M | Sell |
219,511
-97,187
| -31% | -$7.52M | 0.01% | 1217 |
|
|
2013
Q4 | $20.4M | Sell |
316,698
-249,349
| -44% | -$14.9M | 0.01% | 981 |
|
|
2013
Q3 | $36.2M | Sell |
566,047
-96,578
| -15% | -$4.81M | 0.02% | 669 |
|
|
2013
Q2 | $20.5M | Buy |
+662,625
| New | +$17.6M | 0.01% | 959 |
|
Other funds holding ALNY
VPM
VCM
Ameriprise's ALNY Position: Q1 2026 in Review
Ameriprise increased its Alnylam Pharmaceuticals (ALNY) stake by 32% in Q1 2026, buying an estimated $20M and bringing the position to 239,941 shares worth $79.4M. The position accounts for 0.02% of the portfolio, ranked #648.
Ameriprise first reported a position in ALNY in Q2 2013 and has held it in 47 quarters since. The position peaked at $125M in Q3 2023. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Ameriprise held 239,941 shares of Alnylam Pharmaceuticals worth $79.4M as of Q1 2026.
- Ameriprise bought 58,804 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $20M.
- Alnylam Pharmaceuticals made up 0.02% of Ameriprise's portfolio in Q1 2026, its #648 holding.
- Ameriprise first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Ameriprise's Alnylam Pharmaceuticals position peaked at $125M in Q3 2023.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.